Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

December 31, 2026

Conditions

Extensive-stage Small Cell Lung Cancer (ES-SCLC)Cancer - Associated Anorexia - Cachexia Syndrome

Interventions

DRUG

Nanocrystalline megestrol acetate

All Listed Sponsors

lead

Guangzhou Institute of Respiratory Disease

OTHER